Company Insights

XOMA supplier relationships

Explore interactive graphBrowse insights index
XOMA supplier relationship map

XOMA Corp: a royalty‑aggregator that buys future cash flows and runs them for yield

XOMA builds a revenue engine by acquiring royalty and commercial‑payment streams, plus select pipeline assets, then monetizing those streams through royalties, milestone receipts and selective asset sales. The company finances activity with a mix of non‑dilutive credit facilities and equity, and it expands both by buying payment rights from originators and by acquiring small biotechs whose assets can be converted into predictable payment streams. For investors, XOMA’s business model is defined by long‑dated, usage‑based revenue contracts, concentrated purchase transactions, and active portfolio management. Learn more on the NullExposure homepage: https://nullexposure.com/

How the operating model converts biotech risk into cash flow

XOMA’s posture is that of a buyer‑seller: it purchases future payment rights from originators (effectively selling risk-adjusted future royalties to XOMA) and then collects usage‑based royalties and milestone payments as products commercialize. Long‑term contracts dominate the profile — the company explicitly records multi‑year royalty streams (examples include mid‑single‑digit percentages on IXINITY through 2035 and 0.5% on Roche’s faricimab for ten years after first sales) — giving predictable tails to its cash flows, as disclosed in company filings through FY2025.

The capital strategy complements the contract book. XOMA uses non‑dilutive financing (notably a multi‑hundred‑million credit arrangement with Blue Owl Capital in December 2023) to fund acquisitions and share repurchases, preserving ownership while growing the royalty base. Company filings and press coverage document a mix of small ($1–10M), mid ($10–100M) and at least one >$100M purchase consideration for acquisitions between 2023–2025, creating a stepped portfolio concentrated in recently closed deals.

Cash‑generation is usage‑sensitive: XOMA collects usage‑based royalties on approved products (it reported $2.7M in OJEMDA royalties in 2024), while also bearing integration and acquisition execution risk for assets it has recently purchased. Read XOMA supplier intelligence at NullExposure: https://nullexposure.com/

Key operating signals

  • Contracting posture: predominantly purchaser of commercial payment streams (seller role in acquiring rights) with long tenors and usage‑based royalty mechanics (company disclosures, FY2023–FY2025).
  • Concentration: acquisition activity is lumpy — mix of high‑single and double‑digit million dollar deals and at least one >$100M consideration reflecting material portfolio investments (company filings).
  • Criticality: revenues depend on successful commercialization and integration of acquired assets; some streams have already produced material royalties.
  • Maturity: portfolio contains both mature, revenue‑producing royalties and early stage assets that require downstream development or sale.

Supplier and counterparty rundown — what XOMA is buying and who it works with

The following summaries cover every relationship cited in public reports and news excerpts tied to XOMA’s supplier activity.

Mural Oncology plc

XOMA completed the acquisition of Mural Oncology plc on December 5, 2025, a deal that the company expects to fold into its royalty and milestone portfolio as part of its 2025 expansion program, according to a PredictStreet deep dive published via FinancialContent (Dec 13, 2025).

LadRx Corporation

XOMA acquired rights to arimoclomol and aldoxorubicin from LadRx in 2023 as part of a string of portfolio purchases through 2025, a pattern documented in PredictStreet reporting on XOMA’s expansion (FinancialContent, Dec 13, 2025).

LAVA Therapeutics / LAVA Therapeutics N.V.

XOMA purchased assets from LAVA Therapeutics and is focused on integrating those assets into its royalty portfolio; PredictStreet coverage highlights integration and commercialization as the near‑term value drivers (FinancialContent, Dec 13, 2025).

Blue Owl

QuiverQuant reported that interest expense on XOMA’s balance sheet relates to a Blue Owl loan established in December 2023, confirming the company’s use of targeted credit facilities to fund acquisitions and repurchases (QuiverQuant news item on XOMA Q3 2025 results).

Blue Owl Capital

A PredictStreet summary noted a financing arrangement with Blue Owl Capital in December 2023 for up to $140 million, supplying non‑dilutive capital for acquisitions and share activity (FinancialContent, Dec 13, 2025).

HilleVax

XOMA acquired assets from HilleVax in 2025 as part of its aggressive portfolio expansion, and management is integrating those assets to drive future commercial payments (PredictStreet via FinancialContent, Dec 13, 2025).

Turnstone Biologics

Turnstone Biologics was acquired in 2025 and is part of the same expansion batch that includes LAVA and HilleVax; XOMA is consolidating these assets into its royalty pipeline (PredictStreet, FinancialContent, Dec 13, 2025).

Gibson, Dunn & Crutcher LLP

When XOMA Royalty closed its tender offer and completed the acquisition of Generation Bio Inc., Gibson, Dunn & Crutcher acted as legal counsel for XOMA Royalty, as disclosed in a GlobeNewswire release on Feb 9, 2026.

Kinnate Biopharma Inc.

GlobeNewswire reported on April 14, 2025 that XOMA Royalty completed the sale of all five pipeline assets it had acquired from Kinnate Biopharma Inc. (the assets were acquired when XOMA closed its Kinnate acquisition on April 3, 2024).

Rezolute, Inc.

Rezolute, XOMA’s development partner, announced topline results from its Phase 3 sunRIZE study for ersodetug on December 11, 2025, an update referenced in a Markets FinancialContent investor alert on XOMA (Jan 13, 2026).

Mural Oncology (duplicate entry)

PredictStreet coverage also referenced Mural Oncology in the context of asset integration and performance toward commercialization — the integration of Mural assets is a near‑term revenue catalyst for XOMA (FinancialContent, Dec 13, 2025).

Les Laboratoires Servier

A GlobeNewswire press release from 2012 records that Les Laboratoires Servier was a development and commercialization partner for gevokizumab with XOMA, documenting long‑standing collaboration history in XOMA filings (GlobeNewswire, 2012).

Enumeral Biomedical

A BioSpace report from 2018 noted that Enumeral Biomedical filed for bankruptcy and sold assets to XOMA for $1.6 million, reflecting opportunistic asset acquisition strategy in prior years (BioSpace).

Investment implications and operational risks — what matters to buyers and operators

  • Cash predictability is strong where long‑dated, usage‑based contracts exist. The company has multiple multi‑year royalty contracts (e.g., IXINITY through 2035 and faricimab royalty tails). These contracts create durable revenue tails reported in company filings.
  • Earnings volatility is product‑linked and integration‑sensitive. Recent 2024–2025 acquisitions (Mural, LAVA, HilleVax, Turnstone) will determine next‑stage revenue growth; successful integration and commercialization are required to realize returns documented in media coverage.
  • Capital structure lever is meaningful but targeted. The Blue Owl financing provides acquisition firepower with limited dilution, while interest expense is already reflected in results (QuiverQuant Q3 2025 reporting).
  • Deal sizing is concentrated and material. XOMA’s purchase patterns include both small tactical buys and material transactions (evidence of >$100M consideration for at least one deal), so single transactions can move the company’s revenue profile materially.
  • Legal and transactional execution is institutional. Use of top‑tier counsel like Gibson Dunn for tender and acquisition execution reduces transaction risk and signals institutional deal sophistication (GlobeNewswire, Feb 2026).

Read deeper supplier intelligence at NullExposure for transaction‑level analysis: https://nullexposure.com/

Conclusion — XOMA is a specialty acquirer that converts biopharma optionality into royalty cash flows. For investors and counterparties, the core due‑diligence focus should be on the revenue conversion timeline of recent purchases, counterparty commercialization progress, and the company’s cost of capital. For more XOMA relationship briefs and supplier scoring, visit NullExposure: https://nullexposure.com/